Protara Therapeutics (NASDAQ:TARA) and Rigel Pharmaceuticals (NASDAQ:RIGL) Financial Analysis

Rigel Pharmaceuticals (NASDAQ:RIGL) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, institutional ownership and risk.

Risk and Volatility

Rigel Pharmaceuticals has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500.

Insider and Institutional Ownership

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 7.6% of Protara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Rigel Pharmaceuticals and Protara Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	121.50%	47.99%	32.40%
Protara Therapeutics	N/A	-38.70%	-36.02%

Earnings & Valuation

This table compares Rigel Pharmaceuticals and Protara Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28 million	2.57	$367.02 million	$18.72	2.18
Protara Therapeutics	N/A	N/A	-$57.44 million	($1.34)	-3.06

Rigel Pharmaceuticals has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Rigel Pharmaceuticals and Protara Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1	2	3	0	2.33
Protara Therapeutics	1	0	7	0	2.75

Rigel Pharmaceuticals presently has a consensus target price of $54.50, indicating a potential upside of 33.32%. Protara Therapeutics has a consensus target price of $26.25, indicating a potential upside of 539.46%. Given Protara Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Protara Therapeutics is more favorable than Rigel Pharmaceuticals.

Summary

Rigel Pharmaceuticals beats Protara Therapeutics on 9 of the 13 factors compared between the two stocks.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

About Protara Therapeutics

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.